Visiox Pharma Licenses Glaucoma Drug Omlonti from Santen

Visiox Pharma announced it has entered into a definitive agreement with Santen Pharmaceutical to license glaucoma drug Omlonti (omidenepag isopropyl ophthalmic solution 0.002%). Specific financial terms of the deal were not disclosed. 

Omlonti was approved by the FDA in September for the reduction of elevated IOP in patients with primary open-angle glaucoma or ocular hypertension. The approval date was September 22. Omidenepag isopropyl, the active pharmaceutical ingredient in Omlonti, which was developed jointly by Santen and UBE, is a relatively selective prostaglandin EP2 receptor agonist, which increases aqueous humor drainage through the conventional (or trabecular) and uveoscleral outflow pathways, and the only product with this pharmacological action. 

Visiox plans to launch Omlonti in early 2024, followed by once-daily PDP-716 (brimonidine) 0.35%.

"We are pleased to add Omlonti to our innovative pharmaceutical portfolio," Ryan Bleeks, Chief Executive Officer, said in the news release. "We believe this is a compelling transaction, as it expands our addressable market opportunity enhancing our long-term growth and profitability." 

The strategic license provides exclusive rights in the U.S. for product manufacturing and commercialization of Omlonti. Santen will receive an equity stake in Visiox as an upfront payment, and remains eligible to receive sales milestone payments, as well as royalties on net sales of Omlonti in the U.S.